

February 8, 2012

To,
The Manager (Listing),
National Stock Exchange of India Ltd.,
"Exchange Plaza", G-1, Block G,
Bandra-Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir,

Re: Un-Audited Financial Results and Limited Review Report for the quarter ended on 31st December, 2011.

Press Release dated February 8, 2012

With reference to the captioned matter, we enclose herewith the Un-Audited Financial Results of the Company alongwith the Limited Review Report for the quarter ended on 31st December, 2011, which were adopted by the Board of Directors of the Company at its meeting held today i.e. February 8, 2012.

We also send herewith press release dated February 8, 2012.

Kindly take note of the same.

Thanking you,

Yours faithfully,
For **Alembic Pharmaceuticals Limited**


R.K. Baheti
Director-Finance &
Company Secretary

Encl: A/a

CONSOLIDATED				Particulars	STANDALONE			
Quarter Ended on 31 st December 2011	Quarter Ended on 30 th September 2011	Nine months Ended on 31 st December 2011	Year Ended on 31 st March 2011		Quarter Ended on 31 st December 2011	Quarter Ended on 30 th September 2011	Nine months Ended on 31 st December 2011	Year Ended on 31 st March 2011
(Reviewed)	(Reviewed)	(Reviewed)	(Audited)		(Reviewed)	(Reviewed)	(Reviewed)	(Audited)
21766	24902	67391	78805	1 (a) Net Sales / Income from Operations	21766	24902	67391	78805
16516	14903	45168	41859	Domestic	13294	13616	38461	38147
38282	39805	112559	120664	Exports	35060	38518	105852	116952
149	109	403	766	Total	149	109	403	766
38133	39696	112156	119898	Less : Excise Duty	34911	38409	105449	116186
79	103	222	306	Net Sales / Income from Operations	79	103	222	306
				(b) Other Operating Income				
38212	39799	112378	120204	Total Income	34990	38512	105671	116492
250	(2,085)	(3,009)	(472)	2 Expenditure	250	(2,085)	(3,009)	(472)
12916	15422	40140	43494	(a) Decrease/(increase) in stock in trade and work in progress	12916	15422	40140	43494
5774	6038	18357	16018	(b) Consumption of Raw Materials & Packing Materials	3272	4841	12669	12857
3982	3715	11642	14149	(c) Purchase of traded goods	3982	3715	11642	14149
909	1309	3427	4714	(d) Employees' Cost	909	1309	3427	4714
(37)	243	198	664	(e) Research and Development Expense	(37)	243	198	664
7570	9110	23693	25612	(f) Excise Duty	7672	9017	23598	25513
31364	33752	94448	104179	(g) Other Expenditure	28964	32462	88665	100919
6848	6047	17930	16025	Total	6026	6050	17006	15573
13	10	31	8	3 Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	13	10	31	8
6861	6057	17961	16033	4 Other Income	6039	6060	17037	15581
809	845	2473	2959	5 Profit/(Loss) before Interest, Depreciation, & Exceptional Items	809	845	2473	2959
698	708	2083	2389	6 Depreciation	698	708	2083	2389
5354	4504	13405	10685	7 Interest (Net)	4532	4507	12481	10233
964	910	2597	1864	8 Profit/(Loss) after Interest but before Exceptional Items	864	917	2492	1801
(33)	(210)	(175)	282	9 Tax Expense	(33)	(210)	(175)	282
4423	3804	10983	8539	Less : Provision for Current Tax	3701	3800	10164	8150
3770	3770	3770	3770	(Less)/Add : Provision for Deferred Tax (Liability)/Assets	3770	3770	3770	3770
-	-	-	25758	10 Net Profit / (Loss) from Ordinary Activities after Tax	-	-	-	23851
2.35	2.02	5.83	4.53	11 Paid up Equity Share Capital	1.96	2.02	5.39	4.32
48763089	48763089	48763089	48763089	(Face value of share Rs 2/-)	48763089	48763089	48763089	48763089
25.87	25.87	25.87	25.87	12 Reserves excluding Revaluation Reserve	25.87	25.87	25.87	25.87
139752825	139752825	139752825	139752825	13 Basic & Diluted EPS (Not Annualised)	139752825	139752825	139752825	139752825
100.00	100.00	100.00	100.00	14 Public Shareholding	100.00	100.00	100.00	100.00
74.13	74.13	74.13	74.13	- Number of Shares	74.13	74.13	74.13	74.13
				- Percentage of Shareholding				
				15 Promoters and Promoter Group Shareholding				
				Fully Non - Encumbered				
				Number of Shares				
				Percentage of Shares (as a % of the total shareholding of promoter and promoter group)				
				Percentage of Shares (as a % of the total share capital of the Company)				



Notes :

- 1 The above results, which includes unaudited results of the Subsidiary, have been duly reviewed by Statutory Auditors, were recommended by the Audit Committee and were approved by Board of Directors. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website viz www.alembic-india.com and on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com)
- 2 This being the first year of the Company after the demerger becoming effective on 1st April, 2011, the comparable figures for the corresponding quarter/nine months period of the previous financial year were not published. However, the numbers provided in the information memorandum filed with the stock exchanges after receiving Order from the Hon'ble High Court approving the Scheme of demerger are produced below for comparison purpose.

Particulars	(Rs.in Lacs)	
	For the Nine months ended on 31.12.11	For the Nine months ended on 31.12.10
Sales	112559	90891
EBIDTA	17930	13311
PBT	13405	9382
PAT	10983	7511


- 3 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).
- 4 Details of Investor's Complaints for the quarter ended on 31st December, 2011 : Unresolved at the beginning of the quarter-NIL Received during the quarter-12, Disposed off during the quarter-12, Unresolved at the end of the quarter - Nil

Place : Vadodara
Date : 8th Feb, 2012

For Alembic Pharmaceuticals Limited


Chirayu Amin
Chairman and Managing Director

Visit us at www.alembic-india.com



K. S. AIYAR & CO

CHARTERED ACCOUNTANTS

F-7 Laxmi Mills
Shakti Mills Lane (Off Dr E Moses Rd)
Mahalaxmi Mumbai 400 011 India
Tel : 91 22 2493 2502 / 6655 1770
Fax : 91 22 6655 1774
Grams : VERIFY
www.KSAiyar.com
Mail@KSAiyar.com

To,
The Board of Directors;
Alembic Pharmaceuticals Limited;
Alembic Road, Vadodara.

RE: **LIMITED REVIEW OF THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE
QUARTER ENDED 31st December, 2011.**

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Alembic Pharmaceuticals Limited for the quarter ended on 31st December, 2011 and the consolidated year to-date results for the period from 01-04-2011 to 31-12-2011 attached herewith except for the disclosures regarding public shareholding and Promoter and Promoter Group shareholding which have been traced from disclosures made by the management and have not been audited by us. Management is responsible for the preparation and fair presentation of this interim financial information in accordance with Indian Generally Accepted Accounting Principles. Our responsibility is to express a conclusion on this interim financial information based on our review. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors.
2. We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "**Review of Interim Financial Information Performed by the Independent Auditor of the Entity**". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion
3. We report that the consolidated unaudited financial results have been prepared by the Company's management in accordance with the requirements of Accounting Standard (AS) 21 – Consolidated Financial Statements issued by the Institute of Chartered Accountants of India and on the basis of the separate unaudited financial results of the wholly owned subsidiary of the Company (i.e. Alembic Global Holdings SA, Switzerland) which have not been reviewed but are included in the said consolidated results. The unaudited financial results of the



Offices also at
Chennai Kolkata Goa
Bangalore Coimbatore


K. S. AIYAR & CO

CHARTERED ACCOUNTANTS

Subsidiary reflect Company's share in the Revenue of Rs. 3221.48 lacs for the quarter and Rs. 6706.92 lacs for the nine months period ended on 31-12-2011 and in profit of Rs. 723.06 lacs for the quarter and in Profit of Rs. 819.18 lacs for the nine months period ended on 31-12-2011.

4. Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K.S.Aiyar & Co.
Chartered Accountants
FRN: 100186W


Rajesh S. Joshi
Partner
M.No. 38526

Place: Vadodara
Date: 08-02-2012